Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Cilomilast. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B known ✓ | Q07343 | 20/20 | 1.00 |
| ▸ | PDE4A known ✓ | P27815 | 19/20 | 1.00 |
| ▸ | PDE4C known ✓ | Q08493 | 19/20 | 1.00 |
| ▸ | PDE4D known ✓ | Q08499 | 19/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cilomilast SCHEMBL27515 | 1.00 | PDE4B (1.00) | PDE4BPDE4APDE4CPDE4D | |
| Cilomilast SCHEMBL13777301 | 1.00 | PDE4B (1.00) | PDE4BPDE4APDE4CPDE4D | |
| Cilomilast SCHEMBL26372 | 1.00 | PDE4B (1.00) | PDE4BPDE4APDE4CPDE4D | |
| Cilomilast SCHEMBL5975855 | 1.00 | PDE4B (1.00) | PDE4BPDE4APDE4CPDE4D | |
| Cilomilast SCHEMBL6904030 | 0.99 | PDE4B (0.98) | PDE4BPDE4APDE4CPDE4D | |
| Cilomilast SCHEMBL29107422 | 0.99 | PDE4B (0.98) | PDE4BPDE4APDE4CPDE4D | |
| Cilomilast SCHEMBL7130621 | 0.99 | PDE4B (0.98) | PDE4BPDE4APDE4CPDE4D | |
| Cilomilast SCHEMBL7130626 | 0.99 | PDE4B (0.98) | PDE4BPDE4APDE4CPDE4D | |
| Cilomilast SCHEMBL7124080 | 0.97 | PDE4B (0.94) | PDE4BPDE4APDE4CPDE4D | |
| SCHEMBL28381093 | 0.96 | PDE4B (0.92) | PDE4BPDE4APDE4CPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1657 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200237735-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING A PDE4 INHIBITOR AND A P13 DELTA OR DUAL P13 DELTA-GAMMA KINASE INHIBITOR | RHIZEN PHARMACEUTICALS AG (CH) | 2020-07-30 | — | — | US | claimed |
| US-10058539-B2 | Pharmaceutical compositions containing a PDE4 inhibitor and a PI3 delta or dual PI3 delta-gamma kinase inhibitor | RHIZEN PHARMACEUTICALS SA (CH) | 2018-08-28 | — | — | US | claimed |
| US-20170319558-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING A PDE4 INHIBITOR AND A PI3 DELTA OR DUAL PI3 DELTA-GAMMA KINASE INHIBITOR | RHIZEN PHARMACEUTICALS AG (CH) | 2017-11-09 | — | — | US | claimed |
| WO-2017080919-A1 | USE OF PDE4 INHIBITORS FOR THE PROPHYLAXIS AND/OR THERAPY OF DYSLIPOPROTEINAEMIA AND RELATED DISORDERS | ALBERT-LUDWIGS-UNIVERSITÄT FREIBURG (DE) | 2017-05-18 | — | — | WO | claimed |
| EP-3165224-A1 | USE OF PDE4 INHIBITORS FOR THE PROPHYLAXIS AND/OR THERAPY OF DYSLIPOPROTEINAEMIA AND RELATED DISORDERS | Albert-Ludwigs-Universität Freiburg (DE) | 2017-05-10 | — | — | EP | claimed |
| US-20150272936-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING A PDE4 INHIBITOR AND A PI3 DELTA OR DUAL PI3 DELTA-GAMMA KINASE INHIBITOR | RHIZEN PHARMACEUTICALS AG (CH) | 2015-10-01 | — | — | US | claimed |
| EP-2916868-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING A PDE4 INHIBITOR AND A PI3 DELTA OR DUAL PI3 DELTA-GAMMA KINASE INHIBITOR | Rhizen Pharmaceuticals S.A. (CH) | 2015-09-16 | — | — | EP | claimed |
| WO-2014072937-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING A PDE4 INHIBITOR AND A PI3 DELTA OR DUAL PI3 DELTA-GAMMA KINASE INHIBITOR | RHIZEN PHARMACEUTICALS SA (CH) | 2014-05-15 | — | — | WO | claimed |
| EP-2598145-A1 | PHARMACEUTICAL COMPOSITION FOR TREATMENT OF RESPIRATORY AND INFLAMMATORY DISEASES | Boehringer Ingelheim International GmbH (DE) | 2013-06-05 | — | — | EP | claimed |
| US-8273894-B2 | Biphenyl compounds useful as muscarinic receptor antagonists | THERAVANCE, INC. (US) | 2012-09-25 | — | — | US | claimed |
| EP-1279662-A1 | Process for preparing phenylcyclohexan-1-ylcarboxylic acids | SmithKline Beecham Corporation (US) | 2003-01-29 | — | — | EP | claimed |
| US-20020103106-A1 | Methods of inducing ovulation | MERCK SERONO SA (CH) | 2002-08-01 | — | — | US | claimed |
| US-6369108-B1 | CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD). | SMITHKLINE BEECHAM CORPORATION | 2002-04-09 | — | — | US | claimed |
| US-20010056122-A1 | Therapies for treating pulmonary diseases | SMITHKLINE BEECHAM CORPORATION | 2001-12-27 | — | — | US | claimed |
| WO-2001093909-A2 | CANCER TREATMENT COMPOSITION CONTAINING AN ANTI-NEOPLASTIC AGENT AND A PDE4 INHIBITOR | GLAXO GROUP LIMITED (GB) | 2001-12-13 | — | — | WO | claimed |
| US-6288118-B1 | Therapies for treating pulmonary diseases | SMITHKLINE BEECHAM CORPORATION | 2001-09-11 | — | — | US | claimed |
| EP-0633776-B1 | COMPOUNDS USEFUL FOR TREATING ALLERGIC AND INFLAMMATORY DISEASES | SMITHKLINE BEECHAM CORP (US) | 2001-05-09 | — | — | EP | claimed |
| US-6013827-A | Compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2000-01-11 | — | — | US | claimed |
| EP-0919544-A1 | Compounds useful for treating allergic and inflammatory diseases | SMITHKLINE BEECHAM CORPORATION (US) | 1999-06-02 | — | — | EP | claimed |
| US-5552438-A | Compounds useful for treating allergic and inflammatory diseases | SMITHKLINE BEECHAM CORPORATION (US) | 1996-09-03 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170319558-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING A PDE4 INHIBITOR AND A PI3 DELTA OR DUAL PI3 DELTA-GAMMA KINASE INHIBITOR | PIK3CD, PIK3R4, PIK3CG | PDE4B 6/4885PDE4A 5/4885PDE4C 10/4885 |
| US-20200237735-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING A PDE4 INHIBITOR AND A P13 DELTA OR DUAL P13 DELTA-GAMMA KINASE INHIBITOR | PDE4A, PDE12, PDE4B | PDE4B 3/4885PDE4A 1/4885PDE4C 8/4885 |
| US-20020103106-A1 | Methods of inducing ovulation | PDE4A, PDE4B, PDE4C | PDE4B 2/4885PDE4A 1/4885PDE4C 3/4885 |
| US-20150272936-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING A PDE4 INHIBITOR AND A PI3 DELTA OR DUAL PI3 DELTA-GAMMA KINASE INHIBITOR | PIK3CD, PIK3R4, PIK3CG | PDE4B 6/4885PDE4A 5/4885PDE4C 10/4885 |
| US-10058539-B2 | Pharmaceutical compositions containing a PDE4 inhibitor and a PI3 delta or dual PI3 delta-gamma kinase inhibitor | PIK3CD, PIK3R4, PIK3CG | PDE4B 6/4885PDE4A 5/4885PDE4C 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.